| abstract |
The use of an anti-virus effective amount of a β-D-nucleoside derivative or a pharmaceutically acceptable salt or prodrug thereof is described, optionally in a pharmaceutically acceptable carrier or diluent in the manufacture of a medicament for the treatment of hepatitis C virus infection in a host. |